The effects of renal impairment on the pharmacokinetics of zalcitabine

Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1998, Pages 28-33

  Bazunga, Munama ^a,b   Tran, Hieu T ^a,b   Kertland, Heather ^a,b   Chow, Moses S S ^a,b   Massarella, Joseph ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZALCITABINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MALE; ORAL DRUG ADMINISTRATION; STATISTICAL ANALYSIS;

EID: 0031885168     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04373.x     Document Type: Article

References (14)

1. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, et al: Phase I studies of 2′, 3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81.
2. Merigan TC, Skowron G, Bozzette SA, Richman D, Uttamchandani R, Fischl M, et al: Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus infections. Ann Intern Med 1989;110:189-194.
3. Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, et al: Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-769.
4. Pizzo PA, Butler K, Balis F, Brouwers E, Hawkins M, Eddy J, et al: Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990;117:799-808.
5. Meng TC, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, et al: Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 1992;116:13-20.
6. Skowron G, Bozzette AS, Lim L, Pettinelle CB, Schaumburg HH, Arezzo J, et al: Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993;118:321-330.
7. Cooney DA, Ahluwalia G, Mitsuya H, Fridland A, Johnson M, Hao Z, et al: Initial studies on the cellular pharmacology of 2′, 3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1987;36:1765-1768.
8. Starnes MC, Cheng YC: Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem 1987;262:988-991.
9. Klecker RW, Collins JM, Yarchoan R, Thomas R, McAtee N, Broder S, Myers CE, et al: Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988;28:837-842.
10. Nazareno LA, Holazo AA, Limjuco R, Passe S, Twardy SK, Min B, et al: The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1995;12:1462-1465.
11. Massarella JW, Nazareno LA, Passe S, Min B: The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1996;13:449-452.
12. Gustavson LE, Fukuda EK, Rubio FA, Dunton AW: A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr 1990;3:28-31.
13. Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, et al: The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 1987;15:595-601.
14. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.